Home Stock

Stock Research: Jazz Pharmaceuticals

Independent, rules-based stock research to judge this stock's true performance: Cut through market noise and find high-growth or high-value gems from 8,000+ stocks worldwide.

Jazz Pharmaceuticals

NSQ:JAZZ IE00B4Q5ZN47
61
  • Value
    50
  • Growth
    38
  • Safety
    Safety
    44
  • Combined
    27
  • Sentiment
    97
  • 360° View
    360° View
    61
Unlock
What factors are driving this 360° View?
Subscribe to View
Company Description

Jazz Pharmaceuticals plc is a global biopharmaceutical company that develops medicines for serious diseases. It operates in the biopharmaceutical industry, with marketed medicines for sleep disorders, epilepsy, and cancer treatments, including Xywav, Epidiolex, and Rylaze. The company's product candidates include Zanidatamab, Vyxeos, and JZP815. In the last fiscal year, the company had a market cap of $6,803 million, profits of $3,623 million, and revenue of $4,069 million, with 2800 employees.

more

ANALYSIS: With an Obermatt 360° View of 61 (better than 61% compared with alternatives), overall professional sentiment and financial characteristics for the stock Jazz Pharmaceuticals are above average. The 360° View is based on consolidating four consolidated indicators, with half the metrics below and half above average for Jazz Pharmaceuticals. The consolidated Value Rank has an attractive rank of 50, which means that the share price of Jazz Pharmaceuticals is on the lower side compared with the typical size in indicators such as revenues, profits, and invested capital. This means that the stock price is lower than for 50% of alternative stocks in the same industry. The consolidated Sentiment Rank has a good rank of 97, which means that professional investors are more optimistic about the stock than for 97% of alternative investment opportunities. But the consolidated Growth Rank has a low rank of 38, which means that the company exhibits below-average growth momentum when looking at financial metrics such as revenue, profit, invested capital growth, and stock returns. The consolidated Safety Rank has a riskier rank of 44, meaning the company has a riskier financing structure than 56 comparable companies when looking at the amount of its debt, its refinancing requirements, and its ability to service debt. ...read more

more
Strongest Rank Dividend Yield
Weakest Rank Pro Holdings
Country Ireland
Industry Pharmaceuticals
Size Large
Website jazzpharma.com
Index
NASDAQ
D.J. US Health Care
D.J. US Pharmaceutical
S&P MIDCAP
Jazz Pharmaceuticals stock price by TradingView. Not sourced by Obermatt.
Similar Add to Watchlist Similar See Similar Stocks
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 13-Mar-2026.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Value
Identifies how good a value the stock is.
Good Value Expensive
Combined
Consolidated view across Value, Growth, and Safety.
Good Tread Carefully
Growth
Shows a company's growth potential.
High Growth Tough Times
Sentiment
Shows what the market thinks of a stock.
Positive Sentiment Skepticism
Safety
Safety
Assesses how financially secure a company is.
Well-Financed High Leverage
360° View
360° View
Holistic stock analysis: all key non-/financial metrics
Good Watch Out

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
50 53 47 62
Growth
38 63 85 55
Safety
Safety
44 32 20 40
Sentiment
97 82 64 36
360° View
360° View
61 73 59 38
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Analyst Opinions
66 80 72 77
Opinions Change
71 53 75 50
Pro Holdings
n/a 64 45 16
Market Pulse
36 57 33 33
Sentiment
97 82 64 36
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
50 53 47 62
Growth
38 63 85 55
Safety Safety
44 32 20 40
Combined
27 52 48 50
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Price vs. Sales (P/S)
59 48 52 56
Price vs. Earnings (P/E)
56 97 94 90
Price vs. Book (P/B)
62 44 48 62
Dividend Yield
1 1 1 1
Value
50 53 47 62
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Revenue Growth
43 70 50 78
Profit Growth
74 34 79 72
Capital Growth
16 93 92 24
Stock Returns
58 43 30 34
Growth
38 63 85 55
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Leverage
13 7 6 27
Refinancing
76 78 75 74
Liquidity
35 34 21 28
Safety Safety
44 32 20 40

Similar Stocks

Discover high‑ranked alternatives to Jazz Pharmaceuticals and broaden your portfolio horizons.

Grifols

MCE:GRF
Country: Spain
Industry: Biotechnology
Size: X-Large
Full Stock Analysis

Richter Gedeon

BUD:RICHTER
Country: Hungary
Industry: Pharmaceuticals
Size: Large
Full Stock Analysis

Glenveagh Properties

ISE:GVR
Country: Ireland
Industry: Homebuilding
Size: Medium
Full Stock Analysis

Faes Farma

MCE:FAE
Country: Spain
Industry: Pharmaceuticals
Size: Medium
Full Stock Analysis

Frequently Asked
Questions

With good value and positive sentiment, but low growth and risky financing, this combination is generally dangerous as debt requires growth to sustain it. Only investors with a strong belief in future growth potential and a high-risk tolerance should consider this stock.

Obermatt provides unbiased stock analysis as a completely independent third party. We have no conflicts of interest with individual stock titles. Our data-driven analysis is based on algorithms honed over twelve years, giving you analysis that is free from personal bias and conflicts of interest.

The 360° View Rank indicates a company's overall performance across all major financial and non-financial metrics tracked by Obermatt. A 360° View Rank of 75 means the company is more well-rounded than 75% of similar companies. A high score indicates that the company is strong across the board; it is attractively priced, growing sustainably, financially stable, and well-regarded by the market. Learn more.

Become an Obermatt subscriber and see all of the similar stocks here.

OTHER FEATURES

Use the Platform to its Fullest

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.


30-day money back guarantee. Your subscription will renew until you cancel it, which you can do at any time.

What Our Customers Say

See how Obermatt improved their investing:

Review us See More Google Reviews